Skip to main content
SpringerLink
Log in

Investigating the Existence of Quantum Metabolic Values in Non-Hodgkin’s Lymphoma by 2-Deoxy-2-[F-18]fluoro-d-glucose Positron Emission Tomography

  • Research Article
  • Published:
Molecular Imaging and Biology Aims and scope Submit manuscript

Abstract

Objectives

To investigate the existence of quantum metabolic values in various subtypes of non-Hodgkin’s lymphoma (NHL).

Methods

Fifty-eight patients with newly diagnosed NHL and positron emission tomography (PET) performed within three months of biopsy were included. The standardized uptake value (SUV) from PET over the area of biopsy and serum glucose [Glc] were recorded. The group glucose sensitivity(G) for indolent and aggressive NHL was obtained by linear regression with ln(SUV) = G·ln[Glc] + C, where C is a constant for the group. Finally, the individual’s glucose sensitivity (g) was obtained by g = {ln(SUV)-C}/ln[Glc], along with their means in various subtypes of NHL. To further investigate the influence of extreme [Glc] conditions, the SUVs corrected by the individually calculated g at various glucose levels, [Glc′] using SUV′ =SUV·{[Glc′]/[Glc]}g, were compared to the original SUVs for both indolent and aggressive NHL.

Results

The averaged g (=G) for aggressive was significant different from that for indolent NHL (−0.94 ± 0.51 vs. +0.13 ± 0.10, respectively, p < 0.00005). There were significant differences in SUV for [Glc] < 80 or >110 mg/dl for both types of NHL. Unlike overlap among SUVs between NHL subtypes, the g value clearly categorized them into two distinct groups with positive (near-zero) and negative g values (around −1) for the indolent and aggressive NHLs, respectively.

Conclusions

Distinct quantum metabolic values of −1 and 0 were noted in NHL. Aggressive NHL has a more negative value (or higher glucose sensitivity) than that of indolent and, thus, is more susceptible to extreme glucose variation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Elstrom R, Guan L, Baker G, et al. (2003) Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 101:3875–3876

    Article  PubMed  CAS  Google Scholar 

  2. Schoder H, Noy A, Gonen M, et al. (2005) Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin’s lymphoma. J Clin Oncol 23:4643–4651

    Article  PubMed  Google Scholar 

  3. Wong CY, Thie J, Parling-Lynch KJ, et al. (2005) Glucose-normalized standardized uptake value from (18)F-FDG PET in classifying lymphomas. J Nucl Med 46:1659–1663

    PubMed  Google Scholar 

  4. Spaepen K, Stroobants S, Dupont P, et al. (2001) Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin’s lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 19:414–419

    PubMed  CAS  Google Scholar 

  5. Jerusalem G, Beguin Y, Fassotte MF, et al. (1999) Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin’s disease and non-Hodgkin’s lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 94:429–433

    PubMed  CAS  Google Scholar 

  6. Weihrauch MR, Re D, Scheidhauer K, et al. (2001) Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 98:2930–2934

    Article  PubMed  CAS  Google Scholar 

  7. Mikhaeel NG, Timothy AR, O’Doherty MJ, Hain S, Maisey MN (2000) 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin’s lymphoma: comparison with CT. Leuk Lymphoma 39:543–553

    PubMed  CAS  Google Scholar 

  8. Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ (2002) PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin’s disease. J Nucl Med 43:1018–1027

    PubMed  Google Scholar 

  9. Spaepen K, Stroobants S, Dupont P, et al. (2002) Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma. Ann Oncol 13:1356–1363

    Article  PubMed  CAS  Google Scholar 

  10. Fisher RI, Gaynor ER, Dahlberg S, et al. (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med 328:1002–1006

    Article  PubMed  CAS  Google Scholar 

  11. Spaepen K, Stroobants S, Dupont P, et al. (2003) Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood 102:53–59

    Article  PubMed  CAS  Google Scholar 

  12. Becherer A, Mitterbauer M, Jaeger U, et al. (2002) Positron emission tomography with [18F]2-fluoro-d-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation. Leukemia 16:260–267

    Article  PubMed  CAS  Google Scholar 

  13. Huang SC (2000) Anatomy of SUV. Standardized uptake value. Nucl Med Biol 27:643–646

    Article  PubMed  CAS  Google Scholar 

  14. Thie JA, Smith GT, Hubner KF (2005) 2-Deoxy-2-[F-18]fluoro-d: -glucose-positron emission tomography sensitivity to serum glucose: a survey and diagnostic applications. Mol Imaging Biol 7:1–8

    Article  Google Scholar 

  15. Shah N, Hoskin P (2000) The impact of FDG PET imaging on the management of lymphomas. Br J Radiol 73:482–487

    PubMed  CAS  Google Scholar 

  16. Schoder H, Meta J, et al. (2001) Effect of whole-body (18)F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma. J Nucl Med 42:1139–1143

    PubMed  CAS  Google Scholar 

  17. Nakamoto Y, Zasadny KR, Minn H, Wahl RL (2002) Reproducibility of common semi-quantitative parameters for evaluating lung cancer glucose metabolism with positron emission tomography using 2-deoxy-2-[18F]fluoro-d-glucose. Mol Imaging Biol 4:171–178

    Article  PubMed  Google Scholar 

  18. Thie JA (2004) Understanding the standardized uptake value, its methods, and implications for usage. J Nucl Med 45:1431–1434

    PubMed  Google Scholar 

  19. Barrington SF, O’Doherty MJ (2003) Limitations of PET for imaging lymphoma. Eur J Nucl Med Mol Imaging 30(Suppl 1):S117–S127

    Article  PubMed  Google Scholar 

  20. Wong CO, Thie J, Gaskill M, et al. (2006) Addressing glucose sensitivity measured by FDG-PET in lung cancers for radiation treatment planning and monitoring. Int J Radiat Oncol Biol Phys 65:132–137

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

The authors would like to thank the editorial comments and suggestions from the Journal.

Author information

Authors and Affiliations

  1. Positron Diagnostic Center and Cyclotron, Department of Nuclear Medicine, William Beaumont Hospital, 3601 W. Thirteen Mile Road, Royal Oak, MI, 48073-6769, USA

    Ching-yee Oliver Wong MD, PhD, Marianne Gaskill, Surya Chundru MBBS, Darlene Fink-Bennett MD & Conrad Nagle MD

  2. Graduate School of Medicine, University of Tennessee, Knoxville, TN, USA

    Joseph Thie PhD

  3. Division of Medical Oncology, William Beaumont Hospital, Royal Oak, MI, USA

    Kelly J. Parling-Lynch DO, Dana Zakalik MD, Jeffrey H. Margolis MD & Ammar Sukari MD

  4. Cranbrook Schools, Cranbrook Education Community, Bloomfield Hills, MI, USA

    Regina H. Wong

  5. Information Service, William Beaumont Hospital, Royal Oak, MI, USA

    Jack Hill PhD

Authors
  1. Ching-yee Oliver Wong MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joseph Thie PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kelly J. Parling-Lynch DO
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dana Zakalik MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Regina H. Wong
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Marianne Gaskill
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jeffrey H. Margolis MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jack Hill PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ammar Sukari MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Surya Chundru MBBS
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Darlene Fink-Bennett MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Conrad Nagle MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ching-yee Oliver Wong MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wong, Cy.O., Thie, J., Parling-Lynch, K.J. et al. Investigating the Existence of Quantum Metabolic Values in Non-Hodgkin’s Lymphoma by 2-Deoxy-2-[F-18]fluoro-d-glucose Positron Emission Tomography. Mol Imaging Biol 9, 43–49 (2007). https://doi.org/10.1007/s11307-006-0074-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11307-006-0074-z

Key words

Search

Navigation